Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €115.00.

In a report released yesterday, Graham Parry from Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), ...

The newly merged company also formed a subsidiary known as Sanofi Pasteur, which is today one ... manufacturing and marketing of pharmaceutical products. These products are sold principally ...

Sanofi Pasteur and Merial will continue as Sanofi's vaccines and animal health products divisions, respectively, headed by their current bosses Olivier Charmeil and Carsten Hellmann. Sanofi has ...

costly patent expirations of top-selling products as are some rivals. "We've spent five years as a team getting Sanofi to the start line of being a respected R&D machine, and I think the markets ...

Regeneron REGN1.05%increase; green up pointing triangle Pharmaceuticals and Sanofi SAN-0.46%decrease; red down pointing triangle have won U.S. Food and Drug Administration expanded approval of ...

The new bids may exclude parts of the Gold Bond business, a brand that historically sold talc-based products, or seek to leave any future legal risks with Sanofi, said the people.

Sanofi on Friday said it’s in talks with the private equity firm CD&R to sell just over half of its consumer healthcare business, in a deal that could yield billions of dollars for the French ...

Sanofi’s SNY stock has gained 22.7% in the ... driven by higher sales of Dupixent and contributions from new products like Altuviiio and Nexviazyme. Dupixent is now annualizing at close to ...

MANILA, Philippines — French pharmaceutical giant Sanofi Pasteur’s motion for reconsideration on a ruling related to its controversial Dengvaxia dengue vaccine has been denied by the Court of ...